Answers are grounded in this paper and cite their sources.
The discovery of prostate cancer biomarkers has been boosted by the advent of next-generation sequencing (NGS) technologies. Nevertheless, many challenges still exist in exploiting the flood of sequence data and translating them into routine diagnostics and prognosis of prostate cancer. Here we review the recent developments in prostate cancer biomarkers by high throughput sequencing technologies. We highlight some fundamental issues of translational bioinformatics and the potential use of cloud computing in NGS data processing for the improvement of prostate cancer treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: